Overgrowth syndromes and new therapies.

Overgrowth syndromes represent a diverse group of disorders with overlapping features. Interdisciplinary management by a team of experts in vascular anomalies is crucial for establishing the correct diagnosis and optimizing outcomes for these patients. Unique management considerations include increased risk for thrombosis and in some cases, cancer. In recent years, research has demonstrated that these disorders are primarily caused by somatic mutations in growth pathways, particularly the PI3K-mTOR pathway. This improved understanding had led to promising new therapies for this group of patients.

• Publication year

  2020

• Venue

  Seminars in Pediatric Surgery

• Publication date

  2020-09-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.sempedsurg.2020.150974PMID 33069285PMCID PMC11126324
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants

  2020cited by this paper
• Surgical Management of Fibroadipose Vascular Anomaly of the Lower Extremities

  2020cited by this paper
• Embolization Techniques for Arteriovenous Malformations in Parkes-Weber Syndrome.

  2020cited by this paper
• The paradox of cancer genes in non-malignant conditions: implications for precision medicine

  2020cited by this paper
• [A clinical study of Proteus syndrome caused by a mosaic somatic mutation in AKT1 gene].

  2019cited by this paper
• RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation

  2019cited by this paper
• Thrombosis risk factors in PIK3CA‐related overgrowth spectrum and Proteus syndrome

  2019cited by this paper
• The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells

  2019cited by this paper
• Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?

  2019cited by this paper
• ALPELISIB TREATMENT FOR GENITAL VASCULAR MALFORMATION IN CLOVES SYNDROME.

  2019cited by this paper
• Pulmonary thromboembolic events in patients with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal abnormalities and Klippel-Trénaunay syndrome.

  2018cited by this paper
• In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

  2018cited by this paper
• Expanding the clinical and molecular findings in RASA1 capillary malformation-arteriovenous malformation

  2018cited by this paper
• Targeted therapy in patients with PIK3CA-related overgrowth syndrome

  2018cited by this paper
• Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.

  2017cited by this paper
• Parkes Weber syndrome—Diagnostic and management paradigms: A systematic review

  2017cited by this paper
• A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth

  2017cited by this paper
• Abstract 135: A Somatic GNA11 Mutation is Associated with Extremity Capillary Malformation and Overgrowth

  2017cited by this paper
• Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.

  2017cited by this paper
• Wilms tumor screening in diffuse capillary malformation with overgrowth and macrocephaly‐capillary malformation: A retrospective study

  2017cited by this paper
• Cryoablation in fibro-adipose vascular anomaly (FAVA): a minimally invasive treatment option

  2016cited by this paper
• Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies

  2016cited by this paper
• Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies

  2016cited by this paper
• PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation

  2015cited by this paper
• Fibro-Adipose Vascular Anomaly: Clinical-Radiologic-Pathologic Features of a Newly Delineated Disorder of the Extremity

  2014cited by this paper
• Management of visceral vascular anomalies.

  2014cited by this paper
• Overgrowth syndromes with complex vascular anomalies.

  2014cited by this paper
• Capillary malformation–arteriovenous malformation: a clinical review of 45 patients

  2014cited by this paper
• Insuficiencia cardíaca de alto débito secundaria a una fístula arteriovenosa congénita. Síndrome de Parkes Weber

  2013cited by this paper
• Diffuse capillary malformation with overgrowth: a clinical subtype of vascular anomalies with hypertrophy.

  2013cited by this paper
• [High-output cardiac failure due to congenital arteriovenous fistula. Parkes Weber syndrome].

  2013cited by this paper
• RASA1 Mutations and Associated Phenotypes in 68 Families with Capillary Malformation–Arteriovenous Malformation

  2013cited by this paper
• CLOVES syndrome.

  2013cited by this paper
• RASA1 analysis: clinical and molecular findings in a series of consecutive cases.

  2012cited by this paper
• Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.

  2012cited by this paper
• Complex Spinal-Paraspinal Fast-Flow Lesions in CLOVES Syndrome: Analysis of Clinical and Imaging Findings in 6 Patients

  2011cited by this paper
• Management of combined vascular malformations.

  2011cited by this paper
• A mosaic activating mutation in AKT1 associated with the Proteus syndrome.

  2011cited by this paper
• CLOVES syndrome with thoracic and central phlebectasia: increased risk of pulmonary embolism.

  2010cited by this paper
• Diversion venography--a modified technique in Klippel-Trenaunay syndrome: initial experience.

  2010cited by this paper
• High output heart failure caused by extensive arteriovenous malformation: problems and pregnancy

  2009cited by this paper
• Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome

  2009cited by this paper
• CLOVE(S) syndrome: Expanding the acronym

  2009cited by this paper
• A novel mutation in RASA1 causes capillary malformation and limb enlargement

  2008cited by this paper
• Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast‐flow vascular anomalies are caused by RASA1 mutations

  2008cited by this paper
• RASA1: variable phenotype with capillary and arteriovenous malformations.

  2005cited by this paper
• PTEN: One Gene, Many Syndromes

  2003cited by this paper
• PTEN mutations and proteus syndrome.

  2001cited by this paper
• Endorectal pull-through abates gastrointestinal hemorrhage from colorectal venous malformations.

  2000cited by this paper
• PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.

  1999cited by this paper
• Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.

  1998cited by this paper
• Germline PTEN mutations in Cowden syndrome-like families.

  1998cited by this paper

• Prevalence and management of lower limb segmental overgrowth in patients with NF1: an observational study

  2026cites this paper
• Варианты патологических изменений стоп у детей с синдромом Клиппеля–Треноне различной степени тяжести

  2026cites this paper
• Neonatal Cutaneous Vascular Anomalies.

  2025cites this paper
• Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome

  2025cites this paper
• Targeted Medical Therapies for Vascular Anomalies: A Clinical Review

  2025cites this paper
• Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT).

  2024cites this paper
• Vascular anomalies: clinical perspectives

  2022cites this paper
• Clinical and genetic analysis of patients with segmental overgrowth features and somatic mammalian target of rapamycin (mTOR) pathway disruption: Possible novel clinical issues

  2022cites this paper
• Imaging of Vascular Anomalies in the Pediatric Musculoskeletal System.

  2021cites this paper
• Update December 2021

  2021cites this paper